# Generation of false positive SARS-CoV-2 antigen results with testing conditions outside manufacturer recommendations: A scientific approach to pandemic misinformation

Glenn Patriquin[1,2], Ross J. Davidson[1-4], Todd F. Hatchette[1-4], Breanne M. Head[5], Edgard Mejia[5], Michael G. Becker[5], Adrienne Meyers[5], Paul Sandstrom[5], Jacob Hatchette[6], Ava Block[6], Nicole Smith[6], John Ross[6], Jason J. LeBlanc[1-4*]

[1]Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health (NSH), Halifax, Nova Scotia, Canada.

[2]Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.

[3]Department of Medicine (Infectious Diseases), Dalhousie University, Halifax, Nova Scotia, Canada.

[4]Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.

[5]National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, Manitoba, Canada.

[6]Praxes Medical Group, Halifax, Nova Scotia, Canada.

**Key Words:** COVID-19, SARS-CoV-2, antigen, false positive, Panbio

**Abstract word count:** 250

**Body word count:** 2989

***Corresponding author:** Jason J. LeBlanc, PhD, FCCM, D(ABMM)
Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health (NSH),
Room 404B, MacKenzie Building
5788 University Avenue, Halifax, Nova Scotia, B3H 1V8
Tel.: +1 902 473 7698; Fax: +1 902 473 7971
Email: jason.leblanc@nshealth.ca

24 **Abstract**

25 **Objectives.** Antigen-based rapid diagnostics tests (Ag-RDTs) are useful tools for SARS-CoV-2 detection.
26 However, misleading demonstrations of the Abbott Panbio COVID-19 Ag-RDT on social media claimed
27 that SARS-CoV-2 antigen could be detected in municipal water and food products. To offer a scientific
28 rebuttal to pandemic misinformation and disinformation, this study explored the impact of using the
29 Panbio SARS-CoV-2 assay with conditions falling outside of manufacturer recommendations.

30 **Methods.** Using Panbio, various water and food products, laboratory buffers, and SARS-CoV-2-negative
31 clinical specimens were tested, with and without manufacturer buffer. Additional experiments were
32 conducted to assess the role of each Panbio buffer component (tricine, NaCl, pH, and tween-20), as well
33 as the impact of temperatures (4°C, 20°C , and 45°C) and humidity (90%) on assay performance.

34 **Results.** Direct sample testing (without the kit buffer), resulted in false positive signals resembling those
35 obtained with SARS-CoV-2-positive controls tested under proper conditions. The likely explanation of
36 these artifacts is non-specific interactions between the SARS-CoV-2-specific conjugated and capture
37 antibodies, as proteinase K treatment abrogated this phenomenon, and thermal shift assays showed pH-
38 induced conformational changes under conditions promoting artifact formation. Omitting, altering, and
39 reverse engineering the kit buffer all supported the importance of maintaining buffering capacity, ionic
40 strength, and pH for accurate kit function. Interestingly, the Panbio assay could tolerate some extremes
41 of temperature and humidity outside of manufacturer claims.

42 **Conclusions.** Our data support strict adherence to manufacturer instructions to avoid false positive
43 SARS-CoV-2 Ag-RDT reactions, otherwise resulting in anxiety, overuse of public health resources, and
44 dissemination of misinformation.

45

46 **Introduction**

47 High demand for diagnostic testing during the COVID-19 pandemic led to the development of various
48 technologies for SARS-CoV-2 detection.[1] Nucleic acid amplification tests (NAATs), like real-time RT-
49 PCR, are considered the reference methods [2-4], but antigen-based rapid diagnostic tests (Ag-RDTs)
50 have been widely used due to their ease-of use, rapid results, and ability to be performed outside of a
51 laboratory setting.[1] Many Ag-RDTs have been licensed as point-of-care (POC) devices for SARS-CoV-2
52 detection [5,6], but their performance can vary between methods, testing frequency, and settings in
53 which they are used.[7-13] Ag-RDTs are well recognized to be less sensitive and specific than commercial
54 NAATs, and false positive results from Ag-RDTs are known to occur, particularly in settings of low disease
55 prevalence.[14,15]

56 Recently, misleading demonstrations of a SARS-CoV-2 Ag-RDT (i.e. Panbio) on social media platforms
57 have claimed that SARS-CoV-2 antigen can readily be detected in municipal water and commercial food
58 and beverages; however, direct testing of samples onto Ag-RDTs devices is not recommended by the
59 manufacturer. With misinformation and disinformation often perpetuated on social media,
60 unsubstantiated claims can undermine confidence in SARS-CoV-2 diagnostic testing and erode trust in
61 public health efforts. As such, it is important to use science-based approaches to demonstrate that non-
62 specific reactivity can occur when testing is performed under inappropriate conditions, and that SARS-
63 CoV-2 is not truly present in food or potable water samples. This study evaluated conditions that fell
64 outside of those recommended by the manufacturer, which had the potential to generate aberrant Ag-
65 RDT reactions, including unregulated buffering capacity or ionic strength, and extremes of temperature,
66 humidity, and pH.

67 **Materials and methods**

68 *Samples types*

69 Ag-RDT samples included food products (Table S1), water, laboratory buffers, specimen transport media,
70 and 30 each of four different clinical specimens types: 1) nasopharyngeal (NP) swabs in universal
71 transport media (UTM); 2) oropharyngeal and bilateral nares (OP/N) swabs in phosphate buffered saline
72 (PBS) [16,17]; 3) bronchoalveolar lavages (BAL); and 4) saline gargles (Table 1).[18,19]

73 *Antigen and molecular testing*

74 SARS-CoV-2 nucleocapsid antigen detection was performed using the Abbott Panbio COVID-19 Rapid
75 Antigen Test and the BD Veritor System for Rapid Detection of SARS-CoV-2. Each kit's nasal swabs were
76 dipped into the test samples, placed in the appropriate kit buffers, and 3 or 5 drops were used to
77 inoculate the sample wells of the Veritor and Panbio cassettes, respectively, as per the manufacturer
78 recommendations. Each sample was also tested without manufacturer buffer (i.e. direct sample testing),
79 mirroring the procedure and volume recommended for buffer. Results were visualized by the unaided
80 eye after 15 minutes, and Veritor readouts also included automated detection using a BD Veritor Plus
81 instrument. Real-time RT-PCR testing was performed for all specimens except food products using the
82 Roche Diagnostics cobas SARS-CoV-2 Test on the cobas 6800 instrument.

83 *Assessing Panbio buffer components*

84 The exact composition of Panbio buffer is proprietary, yet according to the product insert, it consists of
85 tricine, sodium chloride (NaCl), tween-20, proclin 300, and sodium azide (<0.1%). To assess the role of
86 these components, the buffer was reverse engineered. PCR-grade water (Invitrogen) was chosen as a
87 representative matrix to generate false positive Panbio results (Table 1). Solutions of tricine (1 mM to
88 1M), from pH 3 to 12 were prepared (Figure 1), with or without 1% tween-20. The contribution of ionic
89 strength was assessed using NaCl (1 mM to 1M) in 100 mM tricine solutions pH 3 to 12 (Figure 2).

90

91 *Effect of temperature and humidity on Ag-RDT performance*

92 Dilutions of gamma-irradiated SARS-CoV-2 were assessed at pre-treatment and operational
93 temperatures within (20°C), below (4°C), or above [45°C, 90% relative humidity (RH)] the recommended
94 test conditions (Document S1 and Table S2). Additional experiments evaluated freezing Panbio test
95 components at -20°C, or long-term incubation (16h) at high humidity and temperature (Document S1).
96 To assess the limit of tolerance to water-induced artifacts, Panbio buffer was serially diluted and tested
97 at 4°C, 20°C, and 37°C (Figure 3).

98 *Investigation of environmental conditions on PanBio performance*

99 According to manufacturer specifications, PanBio kits should be stored between 2 to 30 °C, and all kit
100 components brought to room temperature (15 to 30 °C) for 30 minutes prior to use. To assess the
101 impact of storage temperature, sealed PanBio test devices were incubated for one hour at 4°C, 20°C or
102 45°C (with 90% relative humidity using a Binder Constant Climate Chamber model KBF 115). Test devices
103 were removed from their packaging, and incubations were repeated under the same conditions. Testing
104 was performed using 20 µL of gamma-irradiated SARS-CoV-2 into 280 µL of PanBio buffer. Viral stocks
105 [at $1.2 \times 10^6$ plaque forming units (PFU)/mL] were diluted in PBS (pH = 7.4) to concentrations spanning
106 $1.2 \times 10^5$ to $1.1 \times 10^3$ PFU/mL (Supplemental Table S2). PanBio buffer and PBS were used as negative
107 controls. Freeze-thaw effects were investigated by incubation of test components at -20°C for 16 hours
108 before thawing and testing. Long-term exposure to high temperature and humidity was investigated by
109 removing test components from packaging and subjecting them to 16 hours at 45°C (with 90% relative
110 humidity).

111 *Investigations into possible causes of false positive results*

112 Using "conjugate pad transplantation" (Figure S1), the proprietary gold conjugated-antibodies of the
113 Panbio device (i.e. the SARS-CoV-specific human IgG and the chicken IgY used for the control) were
114 accessed from disassembled Panbio cassettes. Each conjugate pad was resuspended with 100 µl of
115 Panbio buffer, PCR-grade water, or tricine solutions, and the suspensions were subjected to various
116 treatments. Proteinase K (PK) (Qiagen GmbH., Hilden, Germany) was used at 100 µg/reaction for one
117 hour at 56°C, followed by enzyme inactivation at 70°C for 10 minutes. Untreated and heat treatment
118 controls were included as controls (Figure S2). The remaining conjugate-free pads are washed three
119 times with 1 ml of water or buffer, dried using a Whatman #1 filter, and re-introduced into the Panbio
120 cassettes. For testing, 25 µl of each water- or buffer-derived conjugated-antibody suspension was added
121 onto the conjugate pads of reassembled cassettes, followed by addition of 5 drops into the sample well
122 of either positive or negative controls processed in water or the kit buffer.

123 In a second set of experiments (Figure S1, dashed lines), the control chicken IgG was removed from the
124 SARS-CoV-2-specific IgG by pre-treatment of the conjugate suspensions with a fragment of the
125 nitrocellulose membrane from the Panbio test device containing the immobilized mouse monoclonal
126 anti-chicken IgY. Fragments were excised at approximately 3 mm on each side of the control line
127 indicated on the Panbio cassette. For each 100 µl of conjugate suspension, one fragment was added,
128 followed by a 15 min incubation at room temperature. Then, SARS-CoV-2-specific conjugated antibody
129 were removed and subjected to thermal shift assays [20-22] to explore possible pH-induced
130 conformational changes (Figure S3).

131 *Conjugated SARS-CoV-2 IgG thermal shift assays*

132 Differential scanning fluorometry (DSF), also known as thermal shift assays, relies on monitoring
133 temperature-dependent unfolding of a protein, in presence of a fluorescent dye that is quenched in
134 water but fluoresces when bound to hydrophobic residues.[20-22] As a native protein is unfolded with

135 heat, different hydrophobic residues are exposed, and the melting temperature (Tm) can be calculated
136 for various test conditions. In this study, 25 µl reaction containing 10× SYPRO Orange (Invitrogen,
137 Eugene, Oregon, USA) was added to the gold-conjugated human IgG specific to SARS-CoV-2
138 resuspended in Panbio buffer or 100 mM of tricine at pH values spanning 3 to 12, with or without 1%
139 tween-20. Melting curve analysis was performed by increasing the temperature from 25°C to 99.9°C at a
140 ramp rate of 1% with continuous fluorescence at 610 nm using an Applied Biosystems 7500 Fast
141 instrument. Tm values were calculated by manufacturer software (Figure S3).

142 **Results**

143 *False positives in food, water, buffers, media, and clinical specimens*

144 With the exception of soft drinks and some milk products which produced negative or weak false
145 positive reactions, most of the food products that were tested directly onto the Panbio cassette
146 produced a strong positive SARS-CoV-2 signals that resembled those obtained with the kit positive
147 control (Table S1). Direct testing of highly acidic samples caused invalid results for both Panbio and
148 Veritor. All other products were Veritor-negative. When nasal swabs were used to sample the various
149 products and processing occurred with manufacturer buffer, no false positives or invalid results were
150 observed.

151 Multiple water samples were evaluated with tested pH values between 4.00 and 9.33, and differences in
152 supplier-described purification methods, and mineral and electrolyte composition (Table 1). Direct
153 testing onto Panbio test devices showed strong false positive SARS-CoV-2 signals, while samples diluted
154 in Panbio buffer did not produce any artifacts. Notably, water samples near the pH of the Panbio buffer
155 (pH 8.78) also displayed strong false positive signals, suggesting the mechanism behind artifact
156 formation is not, or not solely, pH-dependent. To investigate the possible roles of buffering capacity and
157 ionic strength, commonly used laboratory buffers and buffer-containing viral transport media spanning

158 various pH values (5.62 to 8.78) were tested (Table 1). With the exception of Tris-EDTA (TE), all other
159 buffers and media generated weakly positive or negative results (Table 1). All water samples, buffers,
160 and media were RT-PCR and Veritor-negative, suggesting absence of viral RNA and nucleocapsid antigen,
161 respectively (Table 1).

162 Given that weak false positive were results observed with UTM, PBS, and saline, direct testing was
163 performed on clinical specimens containing these media and buffers. With direct testing onto Panbio
164 cassettes, false positive results were seen in 93.3% of NP swabs in UTM, 86.7% of OP/N swabs in PBS,
165 90.0% of BALs, and 90.0% of the saline gargles (Table 1). All specimens were negative when Panbio
166 buffer was used, which was consistent with the Veritor and RT-PCR results.

167 *Role of Panbio buffer components*

168 Tricine solutions at 1M prevented artifact formation at pH values ≥7, whereas strong false positive SARS-
169 CoV-2 results were seen at pH ≤ 5 (Figure 1). At 100 mM tricine, buffering capacity was narrowed, and
170 non-specific SARS-CoV-2 bands were seen at pH ≤ 8. With the exception of invalid results obtained at pH
171 3 and 12, false positive results at either 1 or 10 mM of tricine when pH ranged between 4 and 11.
172 Tween-20 (1%) was added to all tricine solutions, but had no impact on results (data not shown). Ionic
173 strength was assessed with various NaCl concentrations in 100 mM tricine solutions, pH 3 to 12 (Figure
174 2). High concentration of NaCl (1M) prevented artifact formation, 100 mM reduced it, and lower
175 concentrations (1 and 10 mM) mirrored NaCl-free conditions (Figure 1 and 2). Antimicrobial agents in
176 the Panbio buffer (i.e. proclin 300 and sodium azide) were not investigated due to their unlikely
177 contribution to artifact generation.

178 *Investigations into the mechanism of artifact generation*

179 Following conjugate pad transplantation, positive and negative control swabs displayed expected results
180 after inoculation onto re-assembled Panbio cassettes in which resuspended conjugated antibodies were
181 re-introduced. Water-resuspended conjugated antibody generated a strong false positive target signal,
182 which was eliminated following PK treatment (Figure S2). Removal of the gold-conjugated IgY antibody
183 from the conjugate suspensions did not impair Panbio test performance, and the strong false positive
184 SARS-CoV-2 signal from water remained (Figure S2). These findings suggest that the gold-conjugated
185 human anti-SARS-CoV-2 IgG is responsible for the non-specific interactions with the immobilized anti-
186 SARS-CoV-2 capture antibody on the test device nitrocellulose membrane. Thermal shift assays in 100
187 mM tricine solutions were used to compare structural differences of the anti-SARS-CoV-2 IgG at
188 different pH (Figure S3), and Tm values were significantly different in tricine solutions between pH 5 to 7
189 (at 68.4 ± 2.6, 71.4 ± 1.2, 72.5 ± 1.0, respectively) compared to pH 8 to 10 (at 75.6 ± 1.0, 76.8 ± 1.1 and
190 77.6 ± 1.4, respectively) (Figure S3). Tm values at pH 4 and 11 were inconsistent, while no Tm values
191 could be established at pH 3 and 12.

192 *Impact of heat and humidity on Panbio kit function*

193 In all test conditions evaluated (Table S1), no deleterious effects on test sensitivity or specificity were
194 observed concerning temperature or humidity. In a complimentary series of experiments, Panbio buffer
195 was able to tolerate dilutions with water (without generating artifacts) up to a ratio of 1:10, regardless
196 of operating temperature (Figure 3).

197 **Discussion**

198 False positive and negative results occur with any diagnostic test, but are increasingly likely when
199 manufacturer recommendations are not followed.[1,14,15] Using the Panbio SARS-CoV-2 Ag-RDT, this
200 study demonstrated test conditions outside manufacturer recommendations that can cause false
201 positive results. In absence of manufacturer buffer, a variety of food, water, laboratory buffer, specimen

202 transport media, and clinical specimens showed false positive reactions. Uncontrolled conditions of pH,
203 buffering capacity, and ionic strength, all favored artifact generation, whereas temperature and
204 humidity were not contributory under the tested parameters.

205 The principal components of the Panbio buffer, tricine and NaCl, were shown to help maintain buffering
206 capacity, ionic strength, and pH compatible with the proper function of the assay. Panbio buffer diluted
207 in water at ratios greater than 1:10 resulted in artifact formation. Similarly, when buffering capacity was
208 poor or lost when using low tricine concentrations (1 or 10 mM), strong false positive signals were seen
209 across a broad range of pH values. In contrast, high tricine concentrations (100 mM or 1M) prevented
210 artifact formation at pH 9 and above, which is consistent with the measured pH of Panbio buffer at 8.78.
211 Similarly, regulated ionic strength also played an important role, as high NaCl concentrations (100 mM
212 or 1M) reduced or prevented false positive results. Of note, strong artifacts were generated with most
213 food and water samples, due to their poor buffering capacity and ionic strength, whereas only weak
214 positive or negative results seen with buffers, media, and clinical specimens. These data are consistent
215 with others [23] who recognized the importance of Ag-RDT kit buffers.

216 Other possible explanations for false positive Ag-RDT results include cross-reactions [24], interfering
217 substances [25,26], and improper operating or storage conditions for temperature or humidity.[27].
218 Cross-reacting or interfering substances common to all samples tested in the study is unlikely.
219 Temperature extremes have been shown to induce conformational changes in antibodies leading to
220 non-specific binding [28]; however, in this study, Panbio was unaffected by temperature and humidity.
221 As mentioned above, the most likely cause of Panbio false positive results was aberrant protein-protein
222 interactions faced with improper buffer conditions, ionic strength, or pH.

223 In a previous study, 20 of 27 of the malaria Ag-RDTs brands evaluated showed false positive reactions
224 when the manufacturer buffer was replaced with saline, tap water, or distilled water.[23] Distilled water

225 alone generated false positive reactions [23], similar to what was observed in this study with Panbio.
226 Possible explanations for their findings included inefficient resuspension of blocking agents, altered
227 capillary flow rates and decreased flushing of contaminating substances, and finally, non-specific
228 interactions between the conjugated and capture antibodies faced with uncontrolled buffering and ionic
229 strength conditions.[23] Tricine is a zwitterionic amino acid with a pKa of 8.26, and in the Panbio buffer,
230 would be negatively charged at the measured pH of 8.78. Therefore, under recommended testing
231 conditions, tricine may mask positively charged residues on the SARS-CoV-2-specific conjugated and
232 capture antibodies, while uncontrolled buffer conditions would favor aberrant electrostatic or
233 hydrophobic interactions between the two antibodies, resulting in false positive results. Supporting this
234 theory, PK treatment eliminated the false positive Panbio results generated by water, and the
235 propensity to generate this artifact varied with buffering capacity, pH, and ionic strength. Removal of
236 the gold-conjugated chicken IgY (used for control band detection) did not alter formation of the SARS-
237 CoV-2 target artifact formation, suggesting the SARS-CoV-2-specific conjugated IgG alone is responsible
238 for non-specific binding and to the SARS-CoV-2-specific capture antibody and artifact formation. Finally,
239 thermal shift assays were performed on the conjugated anti-SARS-CoV-2 IgG, and pH-dependent
240 conformation changes were observed under conditions causing false positive results.

241 False positive reactions with the Panbio Ag-RDT have the potential to cause a significant impact to Public
242 Health. To date, over 200 million Panbio Ag-RDT tests have been distributed to over 120 countries
243 worldwide, for use in healthcare settings, businesses, or home self-testing. In low prevalence
244 populations, positive Ag-RDTs are typically confirmed by clinical laboratories with NAATs, thereby
245 limiting the overall public health impact of the possible artifacts described in this study.[2-4] However, in
246 programs where home self-testing kits are deployed, it is important to educate users on the importance
247 of strict adherence to manufacturer instructions. Such education could prevent overuse of public health
248 and laboratory resources required to investigate false positive reactions, and may alleviate anxieties for

249 the impacted individuals.[17,19,29,30] Another area for consideration is outdoor testing strategies (e.g.
250 drive-thru testing), where the Panbio kit supplies may be exposed to precipitation and fluctuations in
251 temperature and humidity.[30] To reduce potential aberrant results from humidity, each Panbio
252 cassette is packaged with a desiccant; however, hypothetically, once opened, the accumulation of
253 moisture in humid environments could cause false positive results. Prolonged exposure to elevated
254 temperatures has been shown to affect the sensitivity of SARS-CoV-2 detection by Ag-RDTs, whereas
255 low temperatures impaired specificity.[25] This could potentially impact Ag-RDT programs in countries
256 where extreme environmental conditions are relevant, particularly in those where access to NAAT-
257 based confirmatory testing is limited. While temperature and humidity did not alter the Panbio
258 performance in this study, rain water was shown to cause false positive reactions if processed without
259 buffer. An alternative explanation for the false positives observed at low temperatures by Haage et al
260 [25] is their use of non-validated specimen types (i.e. NP swabs in PBS). In this study, PBS alone caused
261 false positive results in absence of buffer, as did most of the saline-based clinical specimens. While PBS
262 could be a contributing factor in the generation of false positive results, the quantity of PBS material (i.e.
263 20 µl) used by Haage et al.[25] should not have overwhelmed the kit buffer, as this study demonstrated
264 tolerance to dilution up to a ratio of 1:10.

265 Overall, this manuscript provides rigorous scientific evidence that erroneous false positive SARS-CoV-2
266 results can occur with improper test conditions, resulting in non-specific interaction between the SARS-
267 CoV-2-specific conjugated and capture antibodies. As such, SARS-CoV-2 Ag-RDTs should not deviate
268 from manufacturer instructions.

269 **Acknowledgement**

270 The authors would like to thank the Special Pathogens Program of the National Microbiology Laboratory
271 (NML) (Winnipeg, MB) for the gamma-irradiated SARS-CoV-2 virus used in this study. We would also like

272 to recognize the ongoing efforts of the all the NML and NSH staff for their dedication and exceptional
273 services throughout the pandemic, including the help with RT-PCR testing during this evaluation. The
274 authors would also like to thank all the volunteers and healthcare professionals who dedicate their time
275 at popup clinics that use Ag-RDTs. You are all instrumental for our pandemic responses, and safety in
276 our communities.

277 **Author contributions**

278 JH, AB, NS, and JR identified this phenomenon, and were involved in food sample testing. JL, RD, GP, and
279 TH designed and undertook testing of water, buffer, media, and gargles. JL designed and performed the
280 buffer reverse engineering, conjugate pad transplantation, PK experiments and DSF experiments. MB,
281 AM, EM, BH, and PS designed and performed the temperature and humidity experiments. GP, JL, and TH
282 wrote the initial draft of the manuscript, with all authors contributing to the final version.

283 **Transparency declaration**

284 The authors declare that they have no conflicts of interest. This work received no private or public
285 funding, with the exception of the Panbio kits that were provided in-kind from the Public Health Agency
286 of Canada (PHAC).

287 **Ethics**

288 This evaluation was deemed exempt from Nova Scotia Health Research Ethics Board approval, as the
289 activities described in this manuscript were conducted in fulfillment of ongoing verification of SARS-CoV-
290 2 diagnostic assays used in Nova Scotia, and are therefore considered a quality assurance initiative.
291 Clinical specimens tested were obtained from anonymized residual samples collected for routine
292 diagnostic testing for SARS-CoV-2 from consenting participants, and all data related to clinical specimens
293 were provided anonymized, de-identified, and were used solely with the intent to evaluate the potential

294 for false positives in these clinical specimen types for rapid antigen testing programs used in Nova
295 Scotia.

296 **References**


297 1. Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, Oyewunmi OD, Camargo C, Nikpour B, Armanfard N, Sagan SM,
298 Jahanshahi-Anbuhi S. 2021. Tools and techniques for severe acute respiratory syndrome coronavirus
299 2 (SARS-CoV-2)/COVID-19 detection. Clin Microbiol Rev. 34(3):e00228-20. doi: 10.1128/CMR.00228-
300 20. PMID: 33980687.
301 2. Public Health Agency of Canada (PHAC). 2020. Interim guidance on the use of rapid antigen
302 detection tests for the identification of SARS-CoV-2 infection. https://www.canada.ca/en/public-
303 health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/use-rapid-antigen-
304 detection-tests.html (accessed June 21, 2021).
305 3. World Health Organization (WHO). 2020. Antigen-detection in the diagnosis of SARS-CoV-2 infection
306 using rapid immunoassays. Interim guidance. https://www.who.int/publications/i/item/antigen-
307 detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays (accessed June 21,
308 2021)
309 4. Centers for Disease Control and Prevention (CDC). 2020. Interim guidance for antigen testing for
310 SARS-CoV-2. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-
311 guidelines.html (accessed June 21, 2021).
312 5. US Food and Drug Administration. 2020. In vitro diagnostics EUAs. https://www.fda.gov/medical-
313 devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-
314 diagnostics-euas#individual-molecular (accessed June 21, 2021).

315 6. Health Canada. 2020. Authorized medical devices for uses related to COVID-19: List of authorized
316 testing devices. https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-
317 industry/medical-devices/authorized/list.html (accessed June 21, 2021).
318 7. Patriquin G, LeBlanc JJ. SARS-CoV-2 sensitivity limbo - How low can we go? Int J Infect Dis. 2021
319 Feb;103:23-24. doi: 10.1016/j.ijid.2020.11.138. Epub 2020 Nov 17. PMID: 33212261; PMCID:
320 PMC7669480.
321 8. Merino P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán JC, Antona N, Cilla G, Hernáez-
322 Crespo S, Díaz-de Tuesta JL, Gual-de Torrella A, González-Romo F, Escribano P, Sánchez-Castellano
323 MÁ, Sota-Busselo M, Delgado-Iribarren A, García J, Cantón R, Muñoz P, Folgueira MD, Cuenca-
324 Estrella M, Oteo-Iglesias J; Spanish Panbio™ COVID-19 validation group. 2021. Multicenter
325 evaluation of the Panbio COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2
326 infection. Clin Microbiol Infect. 27(5):758-61. doi: 10.1016/j.cmi.2021.02.001. Epub ahead of print.
327 PMID: 33601009; PMCID: PMC7884234.
328 9. Scheiblauer H, Filomena A, Nitsche A, Puyskens A, Corman VM, Drosten C, Zwirglmaier K, Lange C,
329 Emmerich P, Müller M, Knauer O, Nübling CM. 2021. Comparative sensitivity evaluation for 122
330 CE-marked SARS-CoV-2 antigen rapid tests. medRxiv 2021.05.11.21257016; doi:
331 https://doi.org/10.1101/2021.05.11.21257016
332 10. Gremmels H, Winkel BMF, Schuurman R, Rosingh A, Rigter NAM, Rodriguez O, Ubijaan J, Wensing
333 AMJ, Bonten MJM, Hofstra LM. 2021. Real-life validation of the Panbio COVID-19 antigen rapid test
334 (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection.
335 EClinicalMedicine 31:100677. https://doi.org/10.1016/j.eclinm.2020.100677.
336 11. Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F, Gómez-Herruz P, Arroyo T,
337 Cuadros J. 2020. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7

338 days after the onset of symptoms. J Clin Virol. 133:104659. doi: 10.1016/j.jcv.2020.104659. Epub
339 2020 Oct 16. PMID: 33160179; PMCID: PMC7561603.
340 12. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, Martínez M, Poujois S,
341 Forqué L, Valdivia A, Solano de la Asunción C, Ferrer J, Colomina J, Navarro D. 2021. Field evaluation
342 of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary
343 healthcare centres. Clin Microbiol Infect. 27(3):472.e7-472.e10. doi: 10.1016/j.cmi.2020.11.004.
344 Epub 2020 Nov 13. PMID: 33189872; PMCID: PMC7662075.
345 13. Stokes W, Berenger BM, Portnoy D, Scott B, Szelewicki J, Singh T, Venner AA, Turnbull L, Pabbaraju
346 K, Shokoples S, Wong AA, Gill K, Guttridge T, Proctor D, Hu J, Tipples G. 2021. Clinical performance of
347 the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals
348 with COVID-19. Eur J Clin Microbiol Infect Dis. 20:1-6. doi: 10.1007/s10096-021-04202-9. Epub
349 ahead of print. PMID: 33742322; PMCID: PMC7979467.
350 14. Food and Drug Administration (FDA). 2020. Potential for false positive results with antigen tests for
351 rapid detection of SARS-CoV-2 - Letter to clinical laboratory staff and health care providers.
352 https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-positive-results-
353 antigen-tests-rapid-detection-sars-cov-2-letter-clinical-laboratory (accessed June 21, 2021).
354 15. Nikolayevskyy V, Drobniewski F. 2020. False-positive COVID-19 results: hidden problems and costs.
355 Lancet Respir Med. 8(12):1167-1168. doi: 10.1016/S2213-2600(20)30453-7. Epub 2020 Sep 29.
356 PMID: 33007240; PMCID: PMC7524437.
357 16. LeBlanc JJ, Heinstein C, MacDonald J, Pettipas J, Hatchette TF, Patriquin G. 2020. A combined
358 oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of
359 SARS-CoV-2. J Clin Virol. 128:104442. doi: 10.1016/j.jcv.2020.104442. Epub 2020 May 16. PMID:
360 32540034; PMCID: PMC7228872.

361 17. Patriquin G, Davis I, Heinstein C, MacDonald J, Hatchette TF, LeBlanc JJ. 2020. Exploring alternative
362 swabs for use in SARS-CoV-2 detection from the oropharynx and anterior nares. J Virol Methods.
363 285:113948. doi: 10.1016/j.jviromet.2020.113948. Epub 2020 Aug 9. PMID: 32783913; PMCID:
364 PMC7415171.
365 18. Goldfarb DM, Tilley P, Al-Rawahi GN, Srigley JA, Ford G, Pedersen H, Pabbi A, Hannam-Clark S,
366 Charles M, Dittrick M, Gadkar VJ, Pernica JM, Hoang LMN. 2021. Self-collected saline gargle samples
367 as an alternative to health care worker-collected nasopharyngeal swabs for COVID-19 diagnosis in
368 outpatients. J Clin Microbiol. 59(4):e02427-20. doi: 10.1128/JCM.02427-20. PMID: 33514627.
369 19. LeBlanc JJ, Pettipas J, Di Quinzio M, Hatchette TF, Patriquin G. 2021. Reliable detection of SARS-CoV-
370 2 with patient-collected swabs and saline gargles: A three-headed comparison on multiple molecular
371 platforms. Journal of Virological Methods 295:114184. doi: 10.1016/j.jviromet.2021.114184. Epub
372 ahead of print. PMID: 34029634; PMCID: PMC8141269.
373 20. Davey L, Cohen A, LeBlanc J, Halperin SA, Lee SF. 2016. The disulfide oxidoreductase SdbA is active in
374 Streptococcus gordonii using a single C-terminal cysteine of the CXXC motif. Mol Microbiol.
375 99(2):236-53. doi: 10.1111/mmi.13227. Epub 2015 Oct 30. PMID: 26395460.
376 21. Gao K, Oerlemans R, Groves MR. 2020. Theory and applications of differential scanning fluorimetry
377 in early-stage drug discovery. Biophys Rev. 12(1):85-104. doi: 10.1007/s12551-020-00619-2. Epub
378 2020 Jan 31. PMID: 32006251; PMCID: PMC7040159.
379 22. Ramu T, Prasad ME, Connors E, Mishra A, Thomassin JL, LeBlanc JJ, Rainey JK, Thomas NA. 2013. A
380 novel C-terminal region within the multicargo type III secretion chaperone CesT contributes to
381 effector secretion. J Bacteriol. 195(4):740-56. doi: 10.1128/JB.01967-12. Epub 2012 Dec 7. PMID:
382 23222727; PMCID: PMC3562101.

383 23. Gillet P, Mori M, Van den Ende J, Jacobs J. 2010. Buffer substitution in malaria rapid diagnostic tests
384 causes false-positive results. Malar J. 9:215. doi: 10.1186/1475-2875-9-215. PMID: 20650003;
385 PMCID: PMC3224932.
386 24. Wanji S, Amvongo-Adjia N, Njouendou AJ, Kengne-Ouafo JA, Ndongmo WP, Fombad FF, Koudou B,
387 Enyong PA, Bockarie M. 2016. Further evidence of the cross-reactivity of the Binax NOW Filariasis
388 ICT cards to non-Wuchereria bancrofti filariae: experimental studies with Loa loa and Onchocerca
389 ochengi. Parasit Vectors. 9:267. doi: 10.1186/s13071-016-1556-8. PMID: 27151313; PMCID:
390 PMC4858834.
391 25. Selby C. 1999. Interference in immunoassay. Ann Clin Biochem. 36(6):704-21. doi:
392 10.1177/000456329903600603. PMID: 10586307.
393 26. Nivin B, Zancocchio T. 2012. Cluster of false-positive influenza B virus rapid antigen test results in a
394 New York City hospital. J Clin Microbiol. 50(9):3141. doi: 10.1128/JCM.01452-12. Epub 2012 Jun 20.
395 PMID: 22718940; PMCID: PMC3421782.
396 27. Haage V, Ferreira de Oliveira-Filho E, Moreira-Soto A, Kühne A, Fischer C, Sacks JA, Corman VM,
397 Müller MA, Drosten C, Drexler JF. 2021. Impaired performance of SARS-CoV-2 antigen-detecting
398 rapid diagnostic tests at elevated and low temperatures. J Clin Virol. 138:104796. doi:
399 10.1016/j.jcv.2021.104796. Epub 2021 Mar 16. PMID: 33773413; PMCID: PMC7962993.
400 28. Lin J, Dai W, Li W, Xiao L, Luo T, Guo Y, Yang Y, Han Y, Zhu P, Wu Q, He B, Wu J, Xia X. 2021. Potential
401 false-positive and false-negative results for COVID-19 IgG/IgM antibody testing after heat-
402 inactivation. Front Med (Lausanne). 7:589080. doi: 10.3389/fmed.2020.589080. PMID: 33537325;
403 PMCID: PMC7849051.
404 29. Wehrhahn MC, Robson J, Brown S, Bursle E, Byrne S, New D, Chong S, Newcombe JP, Siversten T,
405 Hadlow N. 2020. Self-collection: An appropriate alternative during the SARS-CoV-2 pandemic. J Clin

406 Virol. 128:104417. doi: 10.1016/j.jcv.2020.104417. Epub 2020 May 4. PMID: 32403007; PMCID:
407 PMC7198188.
408 30. Siegler AJ, Hall E, Luisi N, Zlotorzynska M, Wilde G, Sanchez T, Bradley H, Sullivan PS. 2020.
409 Willingness to seek diagnostic testing for SARS-CoV-2 with home, drive-through, and clinic-based
410 specimen collection locations. Open Forum Infect Dis. 7(7):ofaa269. doi: 10.1093/ofid/ofaa269.
411 PMID: 32704517; PMCID: PMC7337815.

412

413 **Figure legends**

414 **Figure 1.** False positives SARS-CoV-2 Ag-RDT results can occur from uncontrolled pH and buffering
415 conditions. All tricine solutions were prepared in PCR-grade water known to generate false positive
416 signals when tested directly onto Panbio test devices.

417 **Figure 2**. Impact of ionic strength from NaCl on the presence of false positive SARS-CoV-2 signal
418 generated by direct processing of PCR-grade water.

419 **Figure 3**. Tolerability of the Panbio buffer to artifact generation by PCR-grade water at different
420 temperatures.

421 **Figure S1**. Conjugate pad transplantation to access and investigate properties of the proprietary Panbio
422 conjugated antibodies. Each step was followed to as depicted leading to treatment of the conjugated
423 antibodies with proteinase K (PK) or heat (T°C), and comparisons were made with untreated controls
424 (none). In some experiments (dashed arrows), the gold-conjugated antibody suspensions were pre-
425 treated with the control antibody (mouse anti-chicken IgY) was used to purify the SARS-CoV-2-specific
426 conjugated antibody (human IgG) for subsequent thermal shift assays.

427 **Figure S2**. Proteainase K treatment of the conjugated antibodies and removal of chicken IgY. A)
428 Proteinase K (PK) treatment. Using conjugate pad transplantation, gold-conjugated antibody
429 suspensions in Panbio buffer or water were treated for an hour with PK at 56°C, followed by heat
430 inactivation of PK at 70°C for 10 min. Following re-introduction into Panbio cassettes of conjugated
431 antibodies that were untreated (none), heat-treated (T°C), or PK-treated, water and a negative control
432 swab, and with buffer with either a positive or negative control swab were added to the sample well. B)
433 To purify the SARS-CoV-2-specific conjugated antibody (human IgG) from the conjugated antibody
434 suspensions, a pre-incubation with the control antibody (mouse anti-chicken IgY) excised from the
435 nitrocellulose membrane was performed. Untreated (none) or pre-treatment (-IgY) are depicted for
436 reassembled Panbio cassettes inoculated with negative or positive control swabs processed in buffer or
437 water.

438 **Figure S3**. Representative thermal shift profiles for Panbio SARS-CoV-2-specific conjugated antibody at
439 different pH values in 100 mM tricine. Melt temperatures (Tm) are indicated for each curve.

440

441

442


pH
3 4 5 6 7 8 9 10 11 12
mM
Tricine
1000
POS POS POS POS NEG NEG NEG NEG NEG NEG
100
POS POS POS POS POS POS NEG NEG NEG NEG
10
INV POS POS POS POS POS POS POS POS INV
1
INV POS POS POS POS POS POS POS POS INV
Control
Target


pH
3 4 5 6 7 8 9 10 11 12
mM
NaCl
1000
NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG
100
POS POS POS POS NEG NEG NEG NEG NEG NEG
10
POS POS POS POS POS NEG NEG NEG NEG NEG
1
POS POS POS POS POS NEG NEG NEG NEG NEG
Control
Target


Panbio buffer:water
(°C)
1:1
1:2
1:4
1:8
1:10
1:20
1:40
1:80
1:100
1:200
1:400
1:800
Temperature
37
NEG NEG NEG NEG NEG POS POS POS POS POS POS POS
Control
Target
25
NEG NEG NEG NEG NEG POS POS POS POS POS POS POS
Control
Target
4
NEG NEG NEG NEG NEG POS POS POS POS POS POS POS
Control
Target

**Table 1.** Samples tested by SARS-CoV-2 Ag-RDTs with and without manufacturer buffer.

| Category | Brand | Description | Avg. pH (± SD) | Panbio result | | Veritor result | | RT-PCR result |
|---|---|---|---|---|---|---|---|---|
| | | | | Sample, direct | Swab of sample in buffer | Sample, direct | Swab of sample in buffer | |
| Water samples (n=24) | Sigma Life Sciences | Double processed, tissue culture water, sterile filtered | 4.00 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Montellier | Carbonated spring water | 4.68 (± 0.00) | POS | NEG | NEG | NEG | NEG |
| | Invitrogen | UltraPure distilled water, Dnase- and Rnase-free | 4.80 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Aquafina | Demineralized water, reverse osmosis | 5.05 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | S. Pellegrino | Carbonated natural mineral water | 5.09 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Canadian Springs | Distilled water, osonized | 5.31 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Dasani | Remineralized water, reverse osmosis treated | 5.68 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Big8 | Distilled water, ozonated | 6.25 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Big8 | Spring water, ozonated | 6.26 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Glaceau Smart | Vapour distilled water with added electrolytes | 6.71 (± 0.02) | POS | NEG | NEG | NEG | NEG |
| | N/A | Municipal water (Halifax, Nova Scotia, May12, 2021) | 6.75 (± 0.02) | POS | NEG | NEG | NEG | NEG |
| | Fiji | Natural spring water, tropical rain filtered through volcanic rock | 7.25 (± 0.02) | POS | NEG | NEG | NEG | NEG |
| | Simple Drop | Natural spring water | 7.26 (± 0.02) | POS | NEG | NEG | NEG | NEG |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Pathwater | Purified water, reverse osmosis treated, ozonated, and electrolytes added, pH-balanced, pH 7.5+ | 7.27 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Art Life WTR | Purified water, mineralized and electrolytes added, pH-balanced | 7.28 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Evian | Spring water, natural electrolytes, pH 7.2 | 7.39 (± 0.02) | POS | NEG | NEG | NEG | NEG |
| | N/A | Rain water (Halifax, Nova Scotia, May 12, 2021) | 7.47 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Icelandic Glacial | Natural spring water | 7.58 (± 0.02) | POS | NEG | NEG | NEG | NEG |
| | Nestle Pure Life | Natural spring water, ozonated | 7.75 (± 0.02) | POS | NEG | NEG | NEG | NEG |
| | Earth Group | Spring water | 7.80 (± 0.03) | POS | NEG | NEG | NEG | NEG |
| | Eska | Natural spring water, pH 7.4 | 7.81 (± 0.00) | POS | NEG | NEG | NEG | NEG |
| | #Smart Moodwater | Naturally alkaline spring water, pH 8+ | 7.91 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Flow | Naturally alkaline spring water, pH 8.1 | 8.02 (± 0.00) | POS | NEG | NEG | NEG | NEG |
| | Glaceau Smart | Mineralized treated water, alkaline pH 9+ | 9.33 (± 0.00) | POS | NEG | NEG | NEG | NEG |
| Laboratory buffers and media (n=14) | Teligent | 0.9% Saline | 5.62 (± 0.02) | POS (weak) | NEG | NEG | NEG | NEG |
| | Boston BioProducts | 0.5M Pipes buffer, pH 6.8 | 6.66 (± 0.01) | POS* | NEG | NEG | NEG | NEG |
| | FisherScientific | 10 mM Tris-HCl; 1 mM EDTA (TE) buffer, molecular-grade pH 7.4 | 7.14 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Sigma Life Sciences | Dulbecco's Phosphate Buffered Saline (PBS) | 7.18 (± 0.01) | POS* | NEG | NEG | NEG | NEG |
| | LiofilChem | Viral Transport Media (VTM) | 7.24 (± 0.01) | POS* | NEG | NEG | NEG | NEG |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Redoxica | Viral Transport Media (VTM) with fetal bovine serum (FBS) | 7.33 (± 0.01) | POS* | NEG | NEG | NEG | NEG |
| | Becton Dickinson | Veritor sample buffer | 7.33 (± 0.00) | NEG | NEG | NEG | NEG | NEG |
| | Copan Diagnostics | Universal Transport Medium (UTM) | 7.37 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| | Yokon | Universal Transport Medium (UTM) | 7.44 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| | Gibco | RPMI medium 1640, with HEPES | 7.48 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| | Genesis | KaiBiLi Extended ViralTrans, includes HEPES | 7.50 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| | Gibco | Minimal Essential Media (MEM) | 7.83 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| | Gibco | 1x Phosphate Buffered Saline (PBS), pH 7.4 | 8.20 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| | Abbott | Panbio sample buffer | 8.78 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| Clinical specimens (n=120) | N/A | NP swabs in UTM (n=30) | N/A | POS* (28/30) | NEG | NEG | NEG | NEG |
| | N/A | OP/N swabs in PBS (n=30) | N/A | POS* (26/30) | NEG | NEG | NEG | NEG |
| | N/A | BALs (n=30) | N/A | POS* (27/30) | NEG | NEG | NEG | NEG |
| | N/A | Saline gargles (n=30) | N/A | POS* (27/30) | NEG | NEG | NEG | NEG |

*Only weak positive reactions were observed.